Anti-Human C5 Recombinant Antibody (Pexelizumab) (CAT#: TAB-901)

Recombinant humanized (from mouse) antibody expressed in CHO binding to human Complement component 5. Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Pharmacodynamics of Pexelizumab.

Figure 1 Pharmacodynamics of Pexelizumab.

Mean hemolytic activity plus or minus standard error versus time of greater than 96 hours after placebo or pexelizumab bolus for all three treatment groups.

Shernan, S. K., Fitch, J. C., Nussmeier, N. A., Chen, J. C., Rollins, S. A., Mojcik, C. F., ... & Gangahar, D. M. (2004). Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. The Annals of thoracic surgery, 77(3), 942-949.

Figure 2 Post hoc assessment of pexelizumab efficacy in isolated coronary artery bypass graft patients across all treatment groups.

Figure 2 Post hoc assessment of pexelizumab efficacy in isolated coronary artery bypass graft patients across all treatment groups.

Data are presented as the incidence of the composite of death or myocardial infarction (any postoperative myocardial-specific isoform of creatine kinase [CK-MB] 100 ng/mL) and its individual components through postoperative day 30. Compared with the placebo group< the pexelizumab bolus plus infusion group reduced myocardial infarction by 66%. Death rates for the pexelizumab bolus plus infusion and placebo populations were 0.4% versus 1.9%, respectively. Error bars represent the standard error of the occurrence rate.

Shernan, S. K., Fitch, J. C., Nussmeier, N. A., Chen, J. C., Rollins, S. A., Mojcik, C. F., ... & Gangahar, D. M. (2004). Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. The Annals of thoracic surgery, 77(3), 942-949.

Figure 3 Histogram of number of enrolled patients in Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery (PRIMO-CABG) I (gray line) compared with PRIMO-CABG II (black line).

Figure 3 Histogram of number of enrolled patients in Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery (PRIMO-CABG) I (gray line) compared with PRIMO-CABG II (black line).

Calculated average intended enrollment threshold for PRIMO-CABG II (vertical line) placed at 2% predicted mortality.

Smith, P. K., Shernan, S. K., Chen, J. C., Carrier, M., Verrier, E. D., Adams, P. X., ... & PRIMO-CABG II Investigators. (2011). Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. The Journal of thoracic and cardiovascular surgery, 142(1), 89-98.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • scFv
  • Species Reactivity
  • Human
  • Applications
  • FuncS, IF, Neut, ELISA, FC, IP, ICC
  • Generic Name
  • Pexelizumab
  • ChEMBL
  • CHZ6OLQ3UU
  • Related Disease
  • Cardiopulmonary bypass (CPB)

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.

Applications

  • Application Notes
  • The C5 antibody has been reported in applications of PD, CK-MB, Inhib.

Target

  • Alternative Names
  • Pexelizumab;h5G1.1-scFv;C5;complement component 5;complement C5;CPAMD4;anaphylatoxin C5a analog;C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4;FLJ17816;FLJ17822;MGC142298;

Related Resources

  • Related Diseases

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "C5"

Neutralizing Antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-088CQ Mouse Anti-C5 Recombinant Antibody (clone CBL771) WB, Block, ELISA Mouse IgG1

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-4104 Hi-Affi™ Rabbit Anti-C5 Recombinant Antibody (clone SI175DS) IHC-P Rabbit IgG

Human Antibody

CAT Product Name Application Type
TAB-453CQ Anti-Human C5 Recombinant Antibody (Tesidolumab) ELISA, IHC, FC, IP, IF, FuncS IgG1, λ2

Recombinant Antibody

CAT Product Name Application Type
HPAB-0609-CN Human Anti-C5 Recombinant Antibody (HPAB-0609-CN) ELISA, Block Humanized IgG
HPAB-0611-CN Rabbit Anti-C5 Recombinant Antibody (HPAB-0611-CN) PK, SPR, IF, ELISA, WB, FC Rabbit IgG
HPAB-0612-CN Human Anti-C5 Recombinant Antibody (HPAB-0612-CN) PK, WB, ELISA, FC Humanized IgG
HPAB-0613-CN Human Anti-C5 Recombinant Antibody (HPAB-0613-CN) WB, ELISA, FC Humanized IgG
HPAB-0614-CN Mouse Anti-C5 Recombinant Antibody (clone m5G1.1) Inhib, FuncS, WB, ELISA, IF, IP, Block Mouse IgG

Single-domain Antibody

CAT Product Name Application Type
PABC-559 Recombinant Llama Anti-C5 Single Domain Antibody (Nb36) ELISA Llama VHH

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-453CQ Afuco™ Anti-C5 ADCC Recombinant Antibody (Tesidolumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-008 Afuco™ Anti-C5 ADCC Recombinant Antibody (Eculizumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-436CQ Afuco™ Anti-C5 ADCC Recombinant Antibody (Olendalizumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-901. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare